Search research articles
Contact Us
Filters
Showing results (171-180 of 281) with videos related to
Page
of 29
Sort By:
Nature Communications
|
June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Cancers
|
December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study
Ymera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 21, 2016
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients
Andrea Sartore-Bianchi, Filippo Pietrantonio, Alessio Amatu, et al.
The Journal of Clinical Investigation
|
July 29, 2010
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, et al.
Nature
|
August 12, 2005
Colorectal cancer: mutations in a signalling pathway
D Williams Parsons, Tian-Li Wang, Yardena Samuels, et al.
Cancers
|
August 7, 2021
Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
Federica Invrea, Simona Punzi, Consalvo Petti, et al.
Cancer Research
|
November 3, 2004
Alterations in vascular gene expression in invasive breast carcinoma
Belinda S Parker, Pedram Argani, Brian P Cook, et al.
Cancer Research
|
October 19, 2016
Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Maud-Emmanuelle Gilles, Federica Maione, Mélissande Cossutta, et al.
Cancer Discovery
|
June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
Med (New York, N.Y.)
|
May 19, 2022
Liquid biopsies for residual disease and recurrence
Jonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.
Page
of 29
Search research articles
Search
Showing results (171-180 of 281) with videos related to
Sort By:
Page
of 29
Nature Communications
|
June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Cancers
|
December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study
Ymera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 21, 2016
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients
Andrea Sartore-Bianchi, Filippo Pietrantonio, Alessio Amatu, et al.
The Journal of Clinical Investigation
|
July 29, 2010
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, et al.
Nature
|
August 12, 2005
Colorectal cancer: mutations in a signalling pathway
D Williams Parsons, Tian-Li Wang, Yardena Samuels, et al.
Cancers
|
August 7, 2021
Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
Federica Invrea, Simona Punzi, Consalvo Petti, et al.
Cancer Research
|
November 3, 2004
Alterations in vascular gene expression in invasive breast carcinoma
Belinda S Parker, Pedram Argani, Brian P Cook, et al.
Cancer Research
|
October 19, 2016
Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Maud-Emmanuelle Gilles, Federica Maione, Mélissande Cossutta, et al.
Cancer Discovery
|
June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
Med (New York, N.Y.)
|
May 19, 2022
Liquid biopsies for residual disease and recurrence
Jonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.
Page
of 29